Dr Denis MullemanRhumatologue à Tours

2026Joint bone spinePubMed

Novel tools for targeted therapies in difficult-to-treat rheumatic diseases

2026The Journal of rheumatologyPubMed

Rethinking Anti-CD20 Therapies: From Fixed to Precision Dosing

2026Clinical and translational sciencePubMed

European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and Perspectives

2026Trends in biotechnologyPubMed

Detection of anti-drug antibodies during monoclonal antibody drug therapy

2026British journal of clinical pharmacologyPubMed

Therapeutic drug monitoring education: The current state

2025Basic & clinical pharmacology & toxicologyPubMed

Quality Assessment of Therapeutic Drug Monitoring Assays of Therapeutic Antibodies Across Europe: An Update

2024Joint bone spinePubMed

Septic arthritis of the facet joint is also a severe vertebral infection: A multicenter retrospective study of 65 patients

2024Basic & clinical pharmacology & toxicologyPubMed

Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe

2024Frontiers in immunologyPubMed

Bispecific antibodies tethering innate receptors induce human tolerant-dendritic cells and regulatory T cells

2023Joint bone spinePubMed

Association between radiographic and functional outcome in vertebral osteomyelitis SPONDIMMO, a 6-month prospective multicenter cohort

2023Annals of the rheumatic diseasesPubMed

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

2022Annals of the rheumatic diseasesPubMed

Management and outcome of native joint septic arthritis: a nationwide survey in French rheumatology departments, 2016-2017

2022Joint bone spinePubMed

Spine immobilization and neurological outcome in vertebral osteomyelitis SPONDIMMO, a prospective multicentric cohort

2019Medecine sciences : M/SPubMed

[Rheumatology, the multitude of options]

2017Therapeutic drug monitoringPubMed

Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling

2017Therapeutic drug monitoringPubMed

Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases

2024Clinical and experimental rheumatologyPubMed

Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts

2024Annals of the rheumatic diseasesPubMed

Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis

2023JAMA network openPubMed

Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies

2021RMD openPubMed

Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials

2026PLoS computational biologyPubMed

Methotrexate's effect on cells and adalimumab immunogenicity in axial spondyloarthritis: A mathematical study

2026Joint bone spinePubMed

Serum biomarkers fail to predict response to adalimumab in axial spondyloarthritis: Results from discovery and validation cohorts

2022Clinical pharmacokineticsPubMed

Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model

2021PharmaceuticsPubMed

Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model

2026PLoS computational biologyPubMed

Methotrexate's effect on cells and adalimumab immunogenicity in axial spondyloarthritis: A mathematical study

2026Joint bone spinePubMed

Serum biomarkers fail to predict response to adalimumab in axial spondyloarthritis: Results from discovery and validation cohorts

2024Clinical and experimental rheumatologyPubMed

Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts

2021Pain medicine (Malden, Mass.)PubMed

A Comparative Study of Fibromyalgia, Rheumatoid Arthritis, Spondyloarthritis, and Sjögren's Syndrome; Impact of the Disease on Quality of Life, Psychological Adjustment, and Use of Coping Strategies

2025Clinical pharmacokineticsPubMed

Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics

2022Clinical pharmacokineticsPubMed

The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition

2020Arthritis research & therapyPubMed

Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study

2020Clinical pharmacokineticsPubMed

Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited

2022Joint bone spinePubMed

High prevalence of clinical and biological features of metabolic syndrome in patients with epidural lipomatosis: A single-center, retrospective study

2021Epidemiology and infectionPubMed

Large increase of vertebral osteomyelitis in France: a 2010-2019 cross-sectional study

2017Clinical and experimental rheumatologyPubMed

High incidence of vertebral osteoporotic fracture within the first year after liver transplantation

2024Joint bone spinePubMed

2023 French recommendations for diagnosing and managing prepatellar and olecranon septic bursitis

2020Joint bone spinePubMed

2020 French recommendations on the management of septic arthritis in an adult native joint

2017Clinical pharmacology : advances and applicationsPubMed

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases

2023Orphanet journal of rare diseasesPubMed

Joint manifestations revealing inborn metabolic diseases in adults: a narrative review

2023RMD openPubMed

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study

2022RMD openPubMed

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider

2026PLoS computational biologyPubMed

Methotrexate's effect on cells and adalimumab immunogenicity in axial spondyloarthritis: A mathematical study

2020RMD openPubMed

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

2025Rheumatology (Oxford, England)PubMed

Inclusion-body myositis associated with Sjögren's disease: clinical characteristics and comparison with other Sjögren-associated myositis

2021Pain medicine (Malden, Mass.)PubMed

A Comparative Study of Fibromyalgia, Rheumatoid Arthritis, Spondyloarthritis, and Sjögren's Syndrome; Impact of the Disease on Quality of Life, Psychological Adjustment, and Use of Coping Strategies

2024Metabolomics : Official journal of the Metabolomic SocietyPubMed

A specific diagnostic metabolome signature in adult IgA vasculitis

2020Clinical pharmacokineticsPubMed

Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited

2023RMD openPubMed

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study

2021Pain medicine (Malden, Mass.)PubMed

A Comparative Study of Fibromyalgia, Rheumatoid Arthritis, Spondyloarthritis, and Sjögren's Syndrome; Impact of the Disease on Quality of Life, Psychological Adjustment, and Use of Coping Strategies

2021Joint bone spinePubMed

Poor assessment of bone mineral density after a forearm fracture in women aged 50 years or older: Data from a French health insurance database

2022Rheumatology internationalPubMed

Machine learning reveals the most important psychological and social variables predicting the differential diagnosis of rheumatic and musculoskeletal diseases

2025Rheumatology (Oxford, England)PubMed

Inclusion-body myositis associated with Sjögren's disease: clinical characteristics and comparison with other Sjögren-associated myositis

2017Therapeutic drug monitoringPubMed

Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics

2024Clinical and experimental rheumatologyPubMed

Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts

2009 · Tours

Variabilité de réponse aux anti TNF-alpha dans les rhumatismes inflammatoires : apport des marqueurs biologiques et d'imagerie.

2019 · doctorant : Amina Bensalem

Pharmacocinétique et relation dose-concentration-effet du rituximab dans la polyartrite rhumatoïde et les vascularités associées aux anticorps anti-cytoplasme des neutrophiles